Drugmakers to be hit by anti-rebate provision

The performance of Korean pharmaceutical companies will be affected in the final quarter by the government’s policy to abandon “rebates” ― a kind of kickback given by drug companies to pharmacies, clinics and hospitals for buying their products.

The local pharmaceutical industry is undergoing a major transformation as tightening regulations and uphill competition combine to reshuffle the lea...